Oncology

Your Article Summary

Recommendations on the use of 18F-FDG PET in oncology
The Journal of Nuclear Medicine, 03/12/08

Fletcher JW et al. - In a trial to develop recommendations on use of 18F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor, it was recommended that 18F-FDG PET should be used as an imaging tool in addition to conventional radiologic methods such as CT or MRI

Methods

• A search was performed to identify all published randomized controlled trials and systematic reviews in the literature
• An additional search was performed to identify relevant unpublished systematic reviews
• Publications comprised both retrospective and prospective studies of varied methodologic quality
• Anticipated consequences of false-positive and false-negative tests when evaluating clinical usefulness, and impact of 18F-FDG PET on management of cancer pts, were also reviewed

Results

• 18F-FDG PET should be used as an imaging tool in addition to conventional radiologic methods such as CT or MRI
• Any positive finding that could lead to a clinically significant change in pt management should be confirmed by subsequent histopathologic examination because of the risk of false-positive results
• 18F-FDG PET should be used in the appropriate clinical setting for the diagnosis of head and neck, lung, or pancreatic cancer and for unknown primary tumor

<< Previous The U.S. Economy And Changes In Health Insurance Coverage,...

Next >> Gain at chromosomal region 5p15.33, containing TERT, is the most...

Contact the Webmaster. Please send us your feedback, questions, and comments and let us know of
any problems you may be experiencing on our site. Thank you for helping us make our site better!

Copyright © 2009 SmartestDoc, a division of M3 USA.